Clinical Trials Logo

Type 2 Diabetes Mellitus (T2DM) clinical trials

View clinical trials related to Type 2 Diabetes Mellitus (T2DM).

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05628090 Completed - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India

PERSISTENT
Start date: November 30, 2022
Phase:
Study type: Observational

The aim of this study is to analyze data from an existing database named SAATH-7 Star, in order to assess the treatment persistence to basal insulin in Type 2 diabetes patients who had been enrolled in the SAATH-7 Star structured patient education program in India.

NCT ID: NCT05607160 Completed - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes

ELDERLY-T
Start date: October 5, 2022
Phase:
Study type: Observational [Patient Registry]

Primary objective: - Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice Secondary objective: - Treatment satisfaction

NCT ID: NCT05294458 Completed - Clinical trials for Chronic Kidney Disease

A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects

Start date: March 28, 2022
Phase: Phase 1
Study type: Interventional

The Sponsor is developing the test medicine, cotadutide, for the potential treatment of non-alcoholic steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) with chronic kidney disease. This healthy volunteer study will try to identify how two different concentrations of cotadutide are taken up by the body when dosed under the skin (subcutaneous injection). The study will also try to identify the absolute bioavailability of cotadutide (amount taken up by the body when dosed under the skin compared to an injection directly into the vein (intravenous)). This is a single-part, three-period study taking place at one non-NHS site in the UK and will involve 12 male and female (non-pregnant/non-lactating) volunteers aged 18-55. For each study period, on Day 1 volunteers will receive cotadutide as either a subcutaneous injection (into the stomach) or an intravenous injection following an overnight fast of at least 10 hours. The subcutaneous injections will be given as either a 1 mg/ml or 5 mg/ml concentration. The intravenous injection will be given as a 0.1 mg/ml concentration. Volunteers will be discharged on Day 4 and there will be a washout period of 7 days between dosing. Blood samples will be taken at regular intervals for pharmacokinetics and safety assessments from Day -1 to discharge. Volunteers will need to return for a follow up visit 28 (±2) days post-first dose for provisional of an anti-drug antibody sample and to ensure wellbeing

NCT ID: NCT04809220 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

AWARD-JPN
Start date: April 13, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.

NCT ID: NCT04504396 Completed - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

Start date: June 23, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 once-weekly subcutaneous doses of PB-119 to subjects with type 2 diabetes mellitus (T2DM) not well-controlled by metformin monotherapy.

NCT ID: NCT04504370 Completed - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

PB119
Start date: April 27, 2020
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 once-weekly subcutaneous doses of PB-119 in Drug-naïve T2DM Subjects.

NCT ID: NCT03774394 Completed - Clinical trials for Coronary Artery Disease (CAD)

Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

Start date: August 22, 2019
Phase: Phase 4
Study type: Interventional

Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk of atherothrombotic events. Clopidogrel is the most widely used platelet P2Y12 receptor inhibitor in patients with coronary artery disease (CAD). However, despite its benefits, many patients still experience recurrent atherothrombotic events. The proposed study will test the central hypothesis that in DM patients the presence of CKD reduces clopidogrel-mediated P2Y12 inhibitory effects through synergistic mechanisms, which include upregulation of the P2Y12 signaling pathway and impaired clopidogrel metabolism.

NCT ID: NCT03656744 Completed - NAFLD Clinical Trials

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Start date: November 26, 2018
Phase: Phase 2
Study type: Interventional

Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.

NCT ID: NCT03604419 Completed - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Start date: June 13, 2018
Phase: Phase 2
Study type: Interventional

A phase 2, multicenter study to evaluate the efficacy and safety of twelve once weekly subcutaneous doses of PB-119 to patients with type 2 diabetes mellitus (T2DM) not well-controlled by metformin mono therapy.

NCT ID: NCT02759107 Completed - Healthy Clinical Trials

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

Start date: May 11, 2016
Phase: Phase 1
Study type: Interventional

The main purposes of this study are to determine: - The safety of tirzepatide and any side effects that might be associated with it. - How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it. - How tirzepatide affects the levels of blood sugar. This study includes 3 parts (A, B and C). Part A involves a single dose of tirzepatide taken as a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in duration, including screening. Parts B and C involve 4 doses of tirzepatide taken once weekly (over 4 weeks) as a SC injection just under the skin and is approximately 12-14 weeks in duration, including screening. Each participant will enroll in only one part. This study is for research purposes only, and is not intended to treat any medical condition.